Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables - Net: 2015-2024

Historic Receivables - Net for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $8.5 million.

  • Intellia Therapeutics' Receivables - Net rose 24.80% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 24.80%. This contributed to the annual value of $8.5 million for FY2024, which is 76.64% down from last year.
  • As of FY2024, Intellia Therapeutics' Receivables - Net stood at $8.5 million, which was down 76.64% from $36.5 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Receivables - Net high stood at $36.5 million for FY2023, and its period low was $2.0 million during FY2021.
  • Over the past 3 years, Intellia Therapeutics' median Receivables - Net value was $8.5 million (recorded in 2024), while the average stood at $16.2 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Receivables - Net surged by 867.52% in 2023, and later plummeted by 76.64% in 2024.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Receivables - Net stood at $2.1 million in 2020, then decreased by 4.65% to $2.0 million in 2021, then skyrocketed by 85.52% to $3.8 million in 2022, then skyrocketed by 867.52% to $36.5 million in 2023, then slumped by 76.64% to $8.5 million in 2024.